NCT00055757View on ClinicalTrials.gov

Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

April 30, 2004

Conditions
Stage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

tipifarnib

Given orally

DRUG

cisplatin

Given IV

DRUG

gemcitabine hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00055757 - Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter